4 months ago
### Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient | Successful Case from The First Affiliated Hospital of Chongqing Medical University CAR-T Th...
4 months ago
Three Major Reasons and Process to Choose Medical Treatment in China Medical Treatment ### High-Quality Medical Care In recent years, China’s medical technology has made significant strides, ...
4 months ago
The Cost of Yescarta: A Comprehensive Overview Introduction Yescarta, known by its generic name axicabtagene ciloleucel, is a groundbreaking chimeric antigen receptor T cell (CAR-T) therapy. Initia...
4 months ago
2024 EHA China Style Professor Pan Jing: Latest Progress of CART T Cell Lymphoma CAR-T cell therapy is flourishing in the field of hematological malignancies, including significant progress in the ...
4 months ago
Long Term Efficacy of CAR-T Novartis Kymriah (Tisagenlecleucel) in the Treatment of Relapsed or Refractory Follicular Lymphoma (R / R FL) Kymriah (Tisagenlecleucel) is a CAR-T cell immunotherapy co...
4 months ago
CAR-T Non-Hodgkin’s Lymphoma, Voice from China at EHA | Prof. Jia Yi’s Team: Superiority of CD19/20 Bispecific CAR-T Therapy in Treating Patients with Relapsed/Refractory B-Cell Lymphom...
4 months ago
CAR-T NHL, The International First Double Negative CAR-T Cell Therapy for Lymphoma Research Results Released, Safe and Effective CAR-T cell therapy is an innovative treatment for cancer. The millio...
4 months ago
Breakthrough in mRNA Cancer Vaccine! Chinese Medical Team Brings New Hope to Advanced Cancer Patients Resistant to Traditional Treatments Cancer Vaccine The rise of mRNA vaccines during the COVID-...
4 months ago
### One Year After Approval: How Effective is China’s First BCMA-Targeted CAR-T Therapy in Treating Multiple Myeloma? Multiple Myeloma “In the past 20 years, the treatment of multiple myelo...
4 months ago
Recent Advances in CAR-T Lymphoma Treatment In recent years, CAR-T cell therapy has been continuously developing and has made significant progress in the field of lymphoma. The 29th Annual Congress...
4 months ago
CAR-T Immunotherapy for Lymphoma: 80-year-old Patient Achieves Cure After 10 Years of Treatment In 2021, the approval of CAR-T cell therapy in China caused a huge sensation and attention, bringing ...
4 months ago
The Total Remission Rate of CAR-T Hodgkin Lymphoma Was 78% • Classical Hodgkin lymphoma (cHL) is a malignant lymphoid disease and the most common subtype of lymphoma. Statistics show that about 93,...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
